These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 32977298)
1. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients. Blancas I; Martín-Pérez FJ; Garrido JM; Rodríguez-Serrano F Breast; 2020 Dec; 54():106-113. PubMed ID: 32977298 [TBL] [Abstract][Full Text] [Related]
2. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients. Matos E; Jug B; Blagus R; Zakotnik B Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108 [TBL] [Abstract][Full Text] [Related]
3. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174 [TBL] [Abstract][Full Text] [Related]
4. Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab. Andersson AE; Linderholm B; Giglio D Acta Oncol; 2021 Apr; 60(4):475-481. PubMed ID: 33191817 [TBL] [Abstract][Full Text] [Related]
5. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762 [TBL] [Abstract][Full Text] [Related]
6. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study. Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160 [TBL] [Abstract][Full Text] [Related]
7. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study. Dhir V; Yan AT; Nisenbaum R; Sloninko J; Connelly KA; Barfett J; Haq R; Kirpalani A; Chan KKW; Petrella TM; Brezden-Masley C Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526 [TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial. Rüger AM; Schneeweiss A; Seiler S; Tesch H; van Mackelenbergh M; Marmé F; Lübbe K; Sinn B; Karn T; Stickeler E; Müller V; Schem C; Denkert C; Fasching PA; Nekljudova V; Garfias-Macedo T; Hasenfuß G; Haverkamp W; Loibl S; von Haehling S J Am Heart Assoc; 2020 Dec; 9(23):e018143. PubMed ID: 33191846 [TBL] [Abstract][Full Text] [Related]
9. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034 [TBL] [Abstract][Full Text] [Related]
10. The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer. Ürun Y; Utkan G; Yalcin B; Akbulut H; Onur H; Oztuna DG; Şenler FC; Demirkazık A; İçli F Exp Oncol; 2015 Mar; 37(1):53-7. PubMed ID: 25804233 [TBL] [Abstract][Full Text] [Related]
11. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Ponde N; Bradbury I; Lambertini M; Ewer M; Campbell C; Ameels H; Zardavas D; Di Cosimo S; Baselga J; Huober J; Izquierdo M; Fumagalli D; Bozovic-Spasojevic I; Maetens M; Harbeck N; Pusztai L; Berghorn M; Im YH; Borrego MR; Chen DR; Rodeheffer R; Piccart M; Suter T; de Azambuja E Breast Cancer Res Treat; 2018 Apr; 168(3):631-638. PubMed ID: 29280043 [TBL] [Abstract][Full Text] [Related]
12. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity. Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102 [TBL] [Abstract][Full Text] [Related]
13. Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients. De Iuliis F; Salerno G; Taglieri L; De Biase L; Lanza R; Cardelli P; Scarpa S Tumour Biol; 2016 Mar; 37(3):3379-87. PubMed ID: 26449821 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer. Şendur MA; Aksoy S; Yorgun H; Ozdemir N; Yilmaz FM; Yazıcı O; Zungun C; Aytemir K; Zengin N; Altundag K Curr Med Res Opin; 2015 Mar; 31(3):547-56. PubMed ID: 25586297 [TBL] [Abstract][Full Text] [Related]
15. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series. Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708 [TBL] [Abstract][Full Text] [Related]
16. Genetic Variability of Antioxidative Mechanisms and Cardiotoxicity after Adjuvant Radiotherapy in HER2-Positive Breast Cancer Patients. Marinko T; Stojanov Konda JT; Dolžan V; Goričar K Dis Markers; 2020; 2020():6645588. PubMed ID: 33425072 [TBL] [Abstract][Full Text] [Related]
17. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854 [TBL] [Abstract][Full Text] [Related]
18. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients. Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636 [TBL] [Abstract][Full Text] [Related]
19. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer. Ben Kridis W; Sghaier S; Charfeddine S; Toumi N; Daoud J; Kammoun S; Khanfir A Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433 [TBL] [Abstract][Full Text] [Related]
20. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]